Published in:
01-07-2002 | Original Research Article
Effects of Oral Contraceptives on the Pharmacokinetics of Moxifloxacin in Premenopausal Women
Published in: Clinical Drug Investigation | Issue 7/2002
Login to get accessAbstract
Objective
This study was conducted to characterise the potential for combination oral contraceptives to negatively impact the pharmacokinetics of oral moxifloxacin due to some similarities in metabolic pathways.
Study participants and methods
15 healthy, premenopausal women using oral contraceptives and 15 using non-hormonal methods of contraception were each administered a single dose of oral moxifloxacin 400mg. Study participants had plasma concentrations of moxifloxacin measured prior to administration and for 48 hours following.
Results
All subjects completed the study and tolerated the drug and methods well. Women receiving oral contraceptives demonstrated a 13% (p = 0.12) decrease in peak plasma concentrations, a 15% (p = 0.008) decrease in area under the plasma concentration-time curve, and a 20% (p = 0.015) increase in total oral clearance, compared with those using non-hormonal methods of contraception.
Conclusions
These changes were most likely the result of the estrogen componnt of the oral contraceptives inducing phase II metabolic pathways of moxifloxacin. The current findings with moxifloxacin are unlikely to be clinicallysignificant except against pathogens with borderline moxifloxacin susceptibilities.